Clotting Disorders

Clotting Disorders

A collection of features and news articles published in ASH Clinical News related to clotting disorders.

Early Catheter Removal Does Not Increase Risk of PE

Among patients with a hematologic malignancy and central venous catheter (CVC)–associated upper extremity deep vein thrombosis (UEDVT), removing CVCs within 48 hours of diagnosis...
On location

Does Khorana Score Accurately Predict VTE in Patients With Uterine and Ovarian Cancer?

At the 2021 ASCO Annual Meeting, researchers shared results from two studies examining the Khorana score for predicting venous thromboembolism (VTE) in patients with...

Dabigatran Etexilate Approved for Children with VTE

The U.S. Food and Drug Administration (FDA) has approved dabigatran etexilate oral pellets for the treatment of children ages three months to 12 years...

Comparing VTE Recurrence, Bleeding, and Death in Isolated Distal Versus Proximal DVT

Patients with isolated distal deep-vein thrombosis (DVT) and proximal DVT have similar long-term rates of venous thromboembolism (VTE) recurrence, bleeding, and death, according to...
On location

Direct Oral Anticoagulants Versus LMWH in Preventing Recurrent VTE in Cancer

At the 2021 ASCO Annual Meeting, two posters reported results from the CANVAS trial, which described the risk-benefit profiles of direct oral anticoagulants (DOACs)...
On location

Edoxaban Likely Prevents VTE Recurrence in Patients With Lung Cancer, Despite High Rates of...

Many clinicians who manage patients with advanced lung cancer have frequently observed high rates of venous thromboembolism (VTE), but neither the incidence of VTE...

Extended Thromboprophylaxis Does Not Reduce VTE Incidence in Hospitalized Patients With Cancer

The use of extended thromboprophylaxis with enoxaparin, betrixaban, or rivaroxaban does not reduce the risk of venous thromboembolic (VTE) events in hospitalized patients with...

Vincent Wagner and Ellen Marcus: Use of the Khorana Score to Predict VTE

Vincent Wagner, MD, and Ellen Marcus, BA, discuss the Khorana score's role in assessing risk of venous thromboembolism (VTE) in patients with gynecological cancers.

Rivaroxaban Reduces Risk of Cardiovascular Events in Patients With Atrial Fibrillation on Hemodialysis

Compared with vitamin K antagonists (VKAs), direct oral anticoagulants (DOACs) are associated with a superior risk-benefit profile in patients with normal renal function or...

High- and Low-Dose Rivaroxaban Versus Aspirin for Women With VTE and Heavy Menstrual Bleeding

Results of a substudy published in Research and Practice in Thrombosis and Haemostasis suggest there is no statistically significant difference in menstrual hemorrhage in...
Advertisement

Current Issue

September 2021 Volume 7 Issue 11

This issue discusses fertility preservation for young patients with cancer, reviews treatment options for primary immune thrombocytopenia, and more.

Block title